Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, respectively, are both looking to develop next-generation versions. A weight loss pill ...

Most major weight-loss drugs are delivered by weekly injections, including Eli Lilly’s popular Zepbound and Novo Nordisk’s (NVO) Wegovy and Ozempic, although a few pills have emerged ...

Medicare drug plans can now cover Lilly’s obesity drug Zepbound for sleep apnea, according to CNBC. There’s a huge demand for the injection, and it opens the door for broader access to it ...

The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...